# Retina is a Marker for Cerebrovascular Heath

> **NCT04753970** · PHASE1,PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 100 (estimated)

## Conditions studied

- Cerebral Small Vessel Diseases
- Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy
- Cerebral Microbleeding
- Sporadic White Matter Disease

## Interventions

- **DRUG:** Cilostazol

## Key facts

- **NCT ID:** NCT04753970
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-02-09
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04753970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04753970, "Retina is a Marker for Cerebrovascular Heath". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04753970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*